EU licenses first pre-pandemic bird flu vaccine
|
|
|
| Posted
:
Sun, 18 May 2008 23:05:03 GMT |
| By
:
Reuters |
| Category
:
US (Business) |
| News Alerts by
Email ( click
here ) |
|
US Business News |
Home
|
|
|
|
By Ben HirschlerLONDON (Reuters) - European authorities have approved the first pre-pandemic bird flu vaccine, Prepandrix, from GlaxoSmithKline Plc , its maker said on Monday.Europe's biggest drugmaker hopes the move will spur fresh stockpile orders from governments around the world.Prepandrix is intended for use before or in the early stages of a flu pandemic. It triggers an immune response to the H5N1 strain of bird flu, which experts fear may trigger a widespread human flu outbreak threatening millions of people.The official license from the European Commission puts Glaxo ahead of rivals in the vaccine race. The green light had been expected, following a positive recommendation from experts at the European Medicines Agency in February.So far, Glaxo has received orders for Prepandrix from a handful of governments, including the United States, Switzerland and Finland. In 2007, it sold 146 million pounds ($284 million) of its pre-pandemic vaccine and bulk antigen.Now Glaxo's flu vaccine head Emmanuel Hanon expects more buyers to follow, justifying the $2 billion his company has invested in increasing flu capacity."It's clear that some governments are more proactive than others ... the policy is evolving and I'm looking for some kind of alignment in terms of what governments are going to do," he told reporters."Governments are concerned by the real medical and economic threat of a pandemic."MASS IMMUNISATIONGlaxo sees governments, rather than the private sector, as the prime market for its new vaccine because of the need to coordinate mass immunization programs.It has previously announced plans to donate 50 million doses of the pre-pandemic vaccine to the World Health Organisation.Other drugmakers including Sanofi-Aventis and Novartis AG are also working on bird flu vaccines and industry analysts say such products may represent a $1 billion-plus sales opportunity for such companies.Glaxo's vaccine should give a degree of protection until a more precisely tailored pandemic vaccine can be produced -- a process likely to take four to six months from the time any pandemic strain is identified.Tests have shown that Prepandrix protects against H5N1 variants currently circulating in Asia, Europe and Africa.The new vaccine contains a special additive, or adjuvant, which allows a very low dose of active ingredient to be used in each shot.A key challenge in producing a vaccine for millions of people around the world is how to make the maximum number of shots from the minimum amount of antigen, or active ingredient.While H5N1 remains mainly a virus affecting birds, scientists say it is the most likely source of the next global flu pandemic in humans, since it may soon mutate into a form that is easily transmitted from person to person.So far, most human cases can be traced to direct or indirect contact with infected birds. The H5N1 virus has killed around 240 people since 2003.(Editing by Jason Neely)
(c) Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
|
|
|
|
|
|
Related News
Five more US bank failures bring total for 2009 to 120
New York - Bank failures in the United States have risen to 120 this year as five more regional institutions were added to the list, the US agency that guarantees the safety of bank deposits said. United Commercial Bank in San Francisco with assets o...
US stocks climb slightly despite double-digit jobless rate
New York - US stocks posted mild gains Friday to end the week as investors shrugged off government figures that put the unemployment rate above 10 per cent. The Labour Department said the jobless rate hit 10.2 per cent in the month of October, the hi...
US joblessness hits 10.2 per cent, highest in 26 years - Summary
Washington - The US unemployment rate surged to 10.2 per cent in October, the highest in 26 years as another 190,000 people lost their jobs, the Labour Department reported Friday. The figure comes after a 9.8-per-cent jobless rate in September and wa...
US joblessness jumps to 10.2 per cent, highest since 1983 - Update
Washington - The US unemployment rate surged to 10.2 per cent in October, the highest in 26 years, as another 190,000 people lost their jobs during the month, the US reported Friday. The figure reported by US Labour Department came after the 9.8 per ...
US jobless rate jumps to 10.2 per cent
Washington - The US unemployment rate surged to 10.2 per cent in October as another 190,000 people lost their jobs, according to US Labour Department figures released Friday. The jobless rate stood at 9.8 per cent in September. Unemployment had been ...
Bulls stop James, edge Cavs - Summary
Los Angeles - The King couldn't deliver in the clutch. Luol Deng and Joakim Noah combined to deny LeBron James a potential game-winning drive in the final seconds as and the visiting Chicago Bulls snapped the Cleveland Cavaliers' three-game winning...
Mortgage lender Fannie Mae posts nearly 19-billion-dollar loss
Washington - US mortgage lender Fannie Mae said Thursday that it would seek 15 billion dollars in federal aid, after posting its ninth consecutive quarterly loss. Fannie Mae reported a net loss of 18.9 billion dollars in the third quarter of 2009, co...
|
|
|
|
|
|
|
|
